1.
Coffee Consumption and Cancer Risk: An Assessment of the Health Implications Based on Recent Knowledge.
Pauwels, EKJ, Volterrani, D
Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2021;30(5):401-411
-
-
-
Free full text
Plain language summary
Coffee is one of the most consumed beverages worldwide. Coffee is a good source of polyphenolic antioxidant and anti-inflammatory compounds such as caffeine, cafestol, kahweol, and chlorogenic acids. This review included one hundred and five cohort studies and meta-analyses to evaluate the relationship between coffee consumption and cancer of the breast, liver, oesophagus, stomach, pancreas, colorectum, kidney, bladder, prostate, and ovaries. The results of this review found an inverse association between coffee consumption and reduced risk of hepatocellular cancer. A slight risk reduction is observed against breast cancer in postmenopausal women. This review found no considerable association between coffee consumption and decreased cancer risk in other organs. Further robust studies are required to investigate the benefits of coffee consumption on cancer risk reduction due to the high heterogeneity of included studies. However, healthcare professionals can use the results of this study to understand the benefits of coffee consumption.
Abstract
A significant number of studies suggest that coffee consumption reduces cancer risk. This beneficial effect is usually ascribed to the presence of polyphenolic antioxidants and anti-inflammatory agents, including caffeine, cafestol, kahweol, and chlorogenic acids. To summarize recent literature on this subject, we performed a bibliographic search in PubMed and Embase over the period January 2005 to December 2020 to identify cohort studies and meta-analysis (with data collection ensuring quality of selected reports) that could provide quantitative data on the relationship between coffee consumption and common cancers. The totality of eligible scientific articles supports the evidence that coffee intake is inversely associated with risk of hepatocellular cancer and, to a slight extent, risk of breast cancer among postmenopausal women. As to the association with other organs, including the esophagus, pancreas, colorectum, kidneys, bladder, ovaries, and prostate, the results are less clear as reports reveal conflicting results or statistically nonsignificant data. Therefore, this overview does not provide broad-based conclusions. Important uncertainties include general study design, inhomogeneous patient sampling, different statistical analysis (deliberate), misreporting of socioeconomic status, education, coffee-brewing methods, consumption of caffeinated or decaffeinated coffee, smoking habits, and alcohol intake. Clearly, more epidemiologic research needs to be conducted before solid science-based recommendations can be made with regard to coffee consumption.
2.
The effects of phosphocreatine disodium salts plus blueberry extract supplementation on muscular strength, power, and endurance.
Anders, JPV, Neltner, TJ, Smith, RW, Keller, JL, Housh, TJ, Daugherty, FJ, Tempesta, MS, Dash, AK, Munt, DJ, Schmidt, RJ, et al
Journal of the International Society of Sports Nutrition. 2021;18(1):60
-
-
-
Free full text
Plain language summary
The effects of polyphenols and phosphocreatine supplementation on exercise performance, muscular strength, power, and endurance are largely unknown. This randomised, double-blinded, placebo-controlled, parallel-design trial aimed to differentiate the effects of a blend of 5 grams of phosphocreatine disodium salts plus 200 mg blueberry extract (PCDSB), 3 grams of Creatinine monohydrate (CM), and placebo on measures of muscular strength, power, and endurance. PCDSB contained 60 grams of phenols and 2.5 grams of pure creatine, and CM contained 2.4 grams of pure creatin. During this trial, thirty-three men took random supplements for 28 days and kept up their regular exercise regimen. In both PCDSB and CM, Peak torque (PT) and Average power (AP) increased after 28 days of supplementation with no effect on fatigue-induced PT% and AP% or body mass. Additionally, a greater proportion of participants showed a meaningful increase in muscular strength to PCDSB than to CM. To evaluate the additive effects of ingredients in the PCDSB supplement, longer-term studies are needed with larger supplementation doses. The study provides insight into the ergogenic effects of PCDSB and CM for healthcare practitioners.
Abstract
BACKGROUND Numerous studies have demonstrated the efficacy of creatine supplementation for improvements in exercise performance. Few studies, however, have examined the effects of phosphocreatine supplementation on exercise performance. Furthermore, while polyphenols have antioxidant and anti-inflammatory properties, little is known regarding the influence of polyphenol supplementation on muscular strength, power, and endurance. Thus, the purpose of the present study was to compare the effects of 28 days of supplementation with phosphocreatine disodium salts plus blueberry extract (PCDSB), creatine monohydrate (CM), and placebo on measures of muscular strength, power, and endurance. METHODS Thirty-three men were randomly assigned to consume either PCDSB, CM, or placebo for 28 days. Peak torque (PT), average power (AP), and percent decline for peak torque (PT%) and average power (AP%) were assessed from a fatigue test consisting of 50 maximal, unilateral, isokinetic leg extensions at 180°·s- 1 before and after the 28 days of supplementation. Individual responses were assessed to examine the proportion of subjects that exceeded a minimal important difference (MID). RESULTS The results demonstrated significant (p < 0.05) improvements in PT for the PCDSB and CM groups from pre- (99.90 ± 22.47 N·m and 99.95 ± 22.50 N·m, respectively) to post-supplementation (119.22 ± 29.87 N·m and 111.97 ± 24.50 N·m, respectively), but no significant (p = 0.112) change for the placebo group. The PCDSB and CM groups also exhibited significant improvements in AP from pre- (140.18 ± 32.08 W and 143.42 ± 33.84 W, respectively) to post-supplementation (170.12 ± 42.68 W and 159.78 ± 31.20 W, respectively), but no significant (p = 0.279) change for the placebo group. A significantly (p < 0.05) greater proportion of subjects in the PCDSB group exceeded the MID for PT compared to the placebo group, but there were no significant (p > 0.05) differences in the proportion of subjects exceeding the MID between the CM and placebo groups or between the CM and PCDSB groups. CONCLUSIONS These findings indicated that for the group mean responses, 28 days of supplementation with both PCDSB and CM resulted in increases in PT and AP. The PCDSB, however, may have an advantage over CM when compared to the placebo group for the proportion of individuals that respond favorably to supplementation with meaningful increases in muscular strength.